Say Goodbye to Your Smartphone
According to Microsoft engineer Alex Kipman, “Smartphones are yesterday's news. The phone is already dead. People just haven't realized.”

And it’s all thanks to the device inside this black box…
Click here to see it in action.
Keith Orford, insider at Calithera Biosciences
Keith Orford Insider Alerts

Get notified the next time Keith Orford buys or sells Calithera Biosciences stock. Enter your email address below to get our daily insider buying and selling report.

Keith Orford Insider Information

Dr. Orford is Chief Medical Officer. Since joining Calithera in 2015, he has overseen clinical development activities, including Clinical Operations and Medical Affairs. Prior to joining Calithera, Dr. Orford was the Clinical Development Lead in the Immuno-Oncology and Combinations Development Performance Unit at GlaxoSmithKline, where he oversaw the clinical activities on multiple early stage clinical trials with targeted agents and novel immune-based therapies. Prior to GlaxoSmithKline, Dr. Orford was at Merck, where he worked on early clinical development programs across oncology and other therapeutic areas. Previously, Dr. Orford was a Research Fellow and Instructor at Massachusetts General Hospital and Harvard Medical School, where he completed clinical training in Internal Medicine, as well as postdoctoral work studying the epigenetic regulation of hematopoietic and embryonic stem cell differentiation. Dr. Orford received his undergraduate, M.D., and Ph.D. degrees from Georgetown University.

What is Keith Orford's net worth?

The estimated net worth of Keith Orford is at least $4,524.00 as of May 22nd, 2019. Dr. Orford owns 10,000 shares of Calithera Biosciences stock worth more than $4,524 as of January 22nd. This net worth approximation does not reflect any other investments that Dr. Orford may own. Learn More.

What is Keith Orford's salary?

As the Director of Calithera Biosciences, Inc., Dr. Orford earned a total compensation package of $1,401,399.00 in 2020. Dr. Orford earned a salary of $455,400.00, a bonus of $149,371.00, options awards of $772,366.00, and other compensation of $24,262.00.

How do I contact Keith Orford?

The corporate mailing address for Dr. Orford and other Calithera Biosciences executives is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. Calithera Biosciences can also be reached via phone at (650) 870-1000 and via email at [email protected]

Has Keith Orford been buying or selling shares of Calithera Biosciences?

Keith Orford has not been actively trading shares of Calithera Biosciences within the last three months. Most recently, Keith Orford sold 48,190 shares of the business's stock in a transaction on Thursday, November 11th. The shares were sold at an average price of $0.88, for a transaction totalling $42,407.20.

Who are Calithera Biosciences' active insiders?

Calithera Biosciences' insider roster includes Susan Molineaux (CEO), and Keith Orford (Director).

Are insiders buying or selling shares of Calithera Biosciences?

During the last twelve months, Calithera Biosciences insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $85,000.00. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 100,000 shares worth more than $85,927.60. The most recent insider tranaction occured on November, 11th when Director Keith Orford sold 48,190 shares worth more than $42,407.20. Insiders at Calithera Biosciences own 11.9 % of the company.

Information on this page was last updated on 11/11/2021.

Keith Orford Insider Trading History at Calithera Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/11/2021Sell48,190$0.88$42,407.20View SEC Filing Icon  
11/9/2021Sell51,810$0.84$43,520.40View SEC Filing Icon  
12/16/2020Sell2,447$6.00$14,682.00View SEC Filing Icon  
6/17/2019Sell417$6.00$2,502.00View SEC Filing Icon  
5/22/2019Sell416$6.00$2,496.0010,000View SEC Filing Icon  
4/15/2019Sell416$6.33$2,633.2810,416View SEC Filing Icon  
3/15/2019Sell417$6.43$2,681.3110,832View SEC Filing Icon  
3/11/2019Sell1,565$6.00$9,390.00View SEC Filing Icon  
10/15/2018Sell313$6.05$1,893.6510,314View SEC Filing Icon  
10/11/2018Sell1,252$6.00$7,512.00View SEC Filing Icon  
7/17/2017Sell2,120$18.31$38,817.20View SEC Filing Icon  
See Full Table

Keith Orford Buying and Selling Activity at Calithera Biosciences

This chart shows Keith Orford's buying and selling at Calithera Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Calithera Biosciences Company Overview

Calithera Biosciences logo
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $0.45
Low: $0.45
High: $0.52

50 Day Range

MA: $0.72
Low: $0.45
High: $1.01

2 Week Range

Now: $0.45
Low: $0.45
High: $3.34


2,882,604 shs

Average Volume

1,453,504 shs

Market Capitalization

$33.90 million

P/E Ratio


Dividend Yield



Grow Your Retirement Account With This Trade!
Whether you’re close to retirement or have barely begun your career, "How To Master the Retirement Trade" by expert Dave Aquino is the guide you’ve been waiting for.

Take advantage of a little known trade window and watch retirement come sooner than you ever thought possible.
Get your copy now!